Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Supriya Lifescience Expands Global Footprint with Esketamine Hydrochloride Approval
Details : Esketamine HCl is a non-selective, non-competitive NMDA receptor antagonist, approved for treating mental illness.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crosslinked Hydrogel
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Kalinga Institute of Technology
Deal Size : Undisclosed
Deal Type : Agreement
Supriya Lifescience Signs Agreement with KIT for Further Development of Wound Healing Gel
Details : Through the agreement, Supriya Lifescience will focus on the advancement of GelHeal, a protein-based crosslinked Hydrogel, gel-based cream, which is being evaluated for the treatment of deep wounds.
Product Name : GelHeal
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
June 11, 2023
Lead Product(s) : Crosslinked Hydrogel
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Kalinga Institute of Technology
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bucillamine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Revive Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
Details : Revive Therapeutics and Indian specialty pharma firm, Supriya Lifescience have signed an MOU to pursue the manufacturing of the API, conduct clinical registration, and commercialize Bucillamine in the treatment of mild-to-moderate COVID-19 in India.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 06, 2021
Lead Product(s) : Bucillamine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Revive Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
KEY PRODUCTS
Reset All
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
